In one study, Cao et al. [75] used paclitaxel to substantially increase the anticancer efficacy of CD47-targeted therapy in late-stage non-Hodgkin lymphoma (NHL) by activating Src family tyrosine kinase signaling in macrophages. The gene discussed is CD47; the disease is non-Hodgkin lymphoma.